Pharmacokinetics of topically applied recombinant human keratinocyte growth factor-2 in alkali-burned and intact rabbit eye. (July 2015)

• Record Type: Journal Article
• Authors: Cai, Jianqiu; Dou, Guifang; Zheng, Long; Yang, Ting; Jia, Xuechao; Tang, Lu; Huang, Yadong; Wu, Wencan; Li, Xiaokun; Wang, Xiaojie
• Is Part Of: Experimental eye research. Volume 136(2015:Jul.)
• Page Start: 93
• Page End: 99
• Publication Date: 2015-07
• Subjects: Keratinocyte growth factor-2 -- Pharmacokinetics -- Radioiodination -- Alkali-burned -- Corneal wound healing; Ophthalmology -- Periodicals; Eye -- Periodicals; Œil -- Périodiques; Ophthalmology; Periodicals; Electronic journals; 612.8405
• DOI: 10.1016/j.exer.2015.05.006
• Languages: English
• ISSNs: 0014-4835

Abstract

Abstract: Keratinocyte growth factor-2 (KGF-2), an effective agent in the development of epithelial tissue and regeneration during corneal wound healing, is a potential therapeutic option to treat the corneal diseases with corneal epithelial defects. However the tissue distribution and pharmacokinetics of KGF-2 have not been explored yet in eye upon topical application. Using 125 I-labeled recombinant human KGF-2 ( 125 I-rhKGF-2), tissue distribution of rhKGF-2 in alkali-burned and control rabbit eyes was studied. Our results revealed that 125 I-rhKGF-2 was distributed to all eye tissues examined. The highest radioactivity level was found in the cornea, followed by iris, sclera, ciliary body, lens, aqueous humor, vitreous body, and serum in a greatest to least order. The levels of 125 I-rhKGF-2 were higher in corneas of alkali-burned eyes than those in control eyes though without statistical significance. Calculated pharmacokinetic parameters of t1/2, Cmax, and Tmax of rhKGF-2 in the rabbit corneas were 3.4 h, 135.2 ng/ml, and 0.5 h, respectively. In iris, lens, aqueous humor, and tear, t1/2, Cmax, and Tmax values were 6.2, 6.5, 5.2, and 2.5 h; 23.2, 4.5, 24.1, and 29, 498.9 ng/ml; and 1.0, 0.5, 0.5, and 1.0 h, respectively. Predominant and rapid accumulation of rhKGF-2 in corneas suggests that therapeutic doses of rhKGF-2 could be delivered by topical application for treatment of corneal diseases. Graphical abstract: Highlights: RhKGF-2 penetrated the cornea epithelium and distributed to all eye tissues examined. The cornea was the primary target tissue of rhKGF-2 by topical application. Predominant accumulation of rhKGF-2 in injured corneas could promote repair process. There was little rhKGF-2 enters into the systemic circulation, which may be a safe factor.